QPS Blog
Featuring news and insights on QPS’ and its Clients’ efforts in providing patients with novel, safe, effective and affordable medicines
DMPK scientists from Exelixis and QPS publish on “Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites” in DMD
dateJuly 27, 2015
dateAbby Doppler, QPS Marketing

Read the original Exelexis-supported publication in Drug Metabolism & Disposition (DMD).

Cabozantinib (COMETRIQ®) inhibits the activity of tyrosine kinases including MET, VEGFRs and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.

Cabozantinib is currently approved by the U.S. Food and Drug Administration for the treatment of progressive, metastatic medullary thyroid cancer (MTC). Cabozantinib - as monotherapy or combination therapy - is the subject of many studies for several cancer indications conducted under the Exelexis Investigator-Sponsored Trial program and in collaboration with the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP).